US2018325846A1PendingUtilityA1

Pharmaceutical formulation for reducing frequency of urination and method of use thereof

58
Assignee: WELLESLEY PHARMACEUTICALS LLCPriority: Jul 8, 2010Filed: May 23, 2018Published: Nov 15, 2018
Est. expiryJul 8, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:David A. DillFrank Rauscher
A61K 31/167A61K 9/0053A61K 31/27A61K 31/437A61K 31/616A61K 2300/00A61K 45/06A61K 31/192
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for reducing frequency of urination are disclosed. The methods comprise administering to a subject having a condition that resulting in undesired frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . A pharmaceutical composition for treating a condition that results in undesired frequency of urination, comprising:
 one or more prostaglandin pathway inhibitors;   one or more analgesic agents, and   a pharmaceutically acceptable carrier.   
     
     
         18 . The pharmaceutical composition of  claim 17 , wherein said one or more prostaglandin pathway inhibitors comprise an inhibitor of prostaglandin activity. 
     
     
         19 . The pharmaceutical composition of  claim 17 , wherein said one or more prostaglandin pathway inhibitors comprise an inhibitor of prostaglandin synthesis. 
     
     
         20 . The pharmaceutical composition of  claim 17 , wherein said one or more prostaglandin pathway inhibitors comprise an inhibitor of prostaglandin transporter activity. 
     
     
         21 . The pharmaceutical composition of  claim 17 , wherein said one or more prostaglandin pathway inhibitors comprise an inhibitor of prostaglandin transporter expression. 
     
     
         22 . The pharmaceutical composition of  claim 17 , wherein said one or more prostaglandin pathway inhibitors comprise an inhibitor of prostaglandin receptor activity. 
     
     
         23 . The pharmaceutical composition of  claim 17 , wherein said one or more prostaglandin pathway inhibitors comprise an inhibitor of prostaglandin receptor expression. 
     
     
         24 - 25 . (canceled) 
     
     
         26 . The pharmaceutical composition of  claim 17 , further comprising an antimuscarinic agent, an antidiuretic, a spasmolytic or zolpidem. 
     
     
         27 . The pharmaceutical composition of  claim 17 , wherein said pharmaceutical composition is formulated for immediate-release. 
     
     
         28 . The pharmaceutical composition of  claim 17 , wherein said pharmaceutical composition is formulated for delayed-release. 
     
     
         29 . The pharmaceutical composition of  claim 17 , wherein said pharmaceutical composition is formulated for extended-release. 
     
     
         30 . The pharmaceutical composition of  claim 29 , wherein said pharmaceutical composition is further coated with an enteric coating. 
     
     
         31 . The pharmaceutical composition of  claim 17 , wherein said pharmaceutical composition is formulated for oral administration. 
     
     
         32 . The pharmaceutical composition of  claim 17 , wherein the one or more analgesic agents comprises acetaminophen. 
     
     
         33 . The pharmaceutical composition of  claim 17 , wherein the one or more analgesic agents comprises ibuprofen 
     
     
         34 . The pharmaceutical composition of  claim 17 , wherein the one or more analgesic agents comprises acetaminophen and ibuprofen.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.